These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12211896)

  • 1. Irrational use of skin-bleaching products can delay the diagnosis of leprosy.
    Mahé A; Ly F; Badiane C; Baldé Y; Dangou JM
    Int J Lepr Other Mycobact Dis; 2002 Jun; 70(2):119-21. PubMed ID: 12211896
    [No Abstract]   [Full Text] [Related]  

  • 2. [Livid streaks induced by bleaching creams].
    Mahé E; Descamps V; Crickx B
    Presse Med; 2003 Mar; 32(10):462. PubMed ID: 12733310
    [No Abstract]   [Full Text] [Related]  

  • 3. Cushing's syndrome and adrenal suppression from percutaneous absorption of clobetasol propionate in infants.
    Cherian MP; AbdulJabbar M
    Saudi Med J; 2001 Dec; 22(12):1139-41. PubMed ID: 11802195
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neuropsychiatric disorders due to clobetasol propionate misuse].
    Law Ping Man L; Poreaux C; Cuny JF; Javot L; Petitpain N; Barbaud A; Schmutz JL
    Therapie; 2013; 68(3):179-81. PubMed ID: 23886466
    [No Abstract]   [Full Text] [Related]  

  • 5. Topical corticosteroids.
    Med Lett Drugs Ther; 1991 Nov; 33(857):108-10. PubMed ID: 1943979
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenal suppression following topical use of clobetasol propionate illegally supplied as a bleaching agent.
    Tobin AM; Barragry J; Kirby B; O'Shea L
    Ir Med J; 2005 Apr; 98(4):118. PubMed ID: 15938560
    [No Abstract]   [Full Text] [Related]  

  • 8. Trichostasis spinulosa: possible association with prolonged topical application of clobetasol propionate 0.05% cream.
    Janjua SA; McKoy KC; Iftikhar N
    Int J Dermatol; 2007 Sep; 46(9):982-5. PubMed ID: 17822507
    [No Abstract]   [Full Text] [Related]  

  • 9. Aesthetic problems associated with the cosmetic use of bleaching products.
    Ly F; Soko AS; Dione DA; Niang SO; Kane A; Bocoum TI; Dieng MT; Ndiaye B
    Int J Dermatol; 2007 Oct; 46 Suppl 1():15-7. PubMed ID: 17919199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
    Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
    Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid action on skin collagen: overview on clinical significance and consequences.
    Nuutinen P; Autio P; Hurskainen T; Oikarinen A
    J Eur Acad Dermatol Venereol; 2001 Jul; 15(4):361-2. PubMed ID: 11730056
    [No Abstract]   [Full Text] [Related]  

  • 12. Cushing's syndrome caused by topical steroid therapy for psoriasis.
    Abma EM; Blanken R; De Heide LJ
    Neth J Med; 2002 Apr; 60(3):148-50. PubMed ID: 12164372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are the effects of local treatment with glucocorticoids only local?
    van Tuyl SA; Slee PH
    Neth J Med; 2002 Apr; 60(3):130-2. PubMed ID: 12164369
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical corticosteroids and bullous pemphigoid.
    Hull CM; McKenna JK; Zone JJ
    Arch Dermatol; 2003 Feb; 139(2):225-6. PubMed ID: 12588236
    [No Abstract]   [Full Text] [Related]  

  • 15. Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis.
    Vázquez-López F; Marghoob AA
    J Am Acad Dermatol; 2004 Nov; 51(5):811-3. PubMed ID: 15523365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic contact dermatitis due to clobetasone butyrate.
    Murata T; Tanaka M; Dekio I; Tanikawa A; Nishikawa T
    Contact Dermatitis; 2000 May; 42(5):305. PubMed ID: 10789866
    [No Abstract]   [Full Text] [Related]  

  • 17. [Skin reactions to topical agents].
    Bachy M
    Sem Hop; 1977 Feb; 53(8):493-6. PubMed ID: 190698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
    Coskun B; Saral Y; Turgut D
    Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [List of compounds used as cosmetics and reported as containing skin-lightening ingredients that are dangerous for health].
    Groupe Thématique 'Peau Noire' de la Société Française de Dermatologie
    Ann Dermatol Venereol; 2011 May; 138(5):443-6. PubMed ID: 21570574
    [No Abstract]   [Full Text] [Related]  

  • 20. Unregulated use of clobetasol propionate.
    Keane FM; Munn SE; Taylor NF; du Vivier AW
    Br J Dermatol; 2001 May; 144(5):1095-6. PubMed ID: 11359411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.